EMA validates submission of Marketing Authorization Application for skin cancer treatment Nidlegy: Sun Pharma, Philogen Ruchika Sharma5 July 2024 9:00 AMMumbai: Sun Pharmaceutical Industries Limited and Philogen S.p.A. have announced that the European Medicines Agency (EMA) validated the...
Sun Pharma, Philogen seek EMA marketing nod for skin cancer treatment Nidlegy Ruchika Sharma4 Jun 2024 11:15 AMMumbai: Philogen S.p.A. and Sun Pharmaceutical Industries Limited have announced the submission of a Marketing Authorization Application (MAA)...
Results of Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024 Ruchika Sharma1 Jun 2024 6:00 AMMumbai: Philogen S.p.A. and Sun Pharmaceutical Industries Limited have announced that the primary results of the Nidlegy Phase III PIVOTAL...
Sun Pharma reports 16.5 percent rise in net profit to Rs 2,523.8 crore in Q3 Ruchika Sharma1 Feb 2024 9:45 AMMumbai: Sun Pharmaceutical Industries Ltd has reported a 16.52 per cent rise in its consolidated net profit to Rs 2,523.8 crore in the third...
Sun Pharma announces positive Phase III results for Nidlegy in locally advanced fully resectable melanoma patients Ruchika Sharma16 Oct 2023 9:19 AMNidlegy is also being developed in dedicated Phase II clinical trials for the treatment of aggressive forms of non-melanoma skin cancer, including...
Sun Pharma, Philogen collaborate to commercialise anti-cancer biopharmaceutical Nidlegy in Europe, Australia and New Zealand Ruchika Sharma30 May 2023 7:04 AMThe two partner companies will share post-commercialization economics in about 50:50 ratio.
